The approval covers multiple strengths of Semaglutide Injection, including 0.25 mg {(1mg /1.5ml) (0.68 mg/ml)}, 0.5 mg {(2 mg/1.5ml) (1.34 mg/ml)}, 1mg {(4 mg/3ml) (1.34 mg/ml)}, 1.7 mg {(6.8 mg/3 ml) (2.27 mg/ml)} & 2.4 mg {(9.6 mg/3 ml) (3.2 mg/ml) (Synthetic origin).
The Committee specified that the drug is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m² or greater (obesity), or 27 kg/m² or greater (overweight) in the presence of at least one weight-related comorbid condition, such as hypertension, type 2 diabetes mellitus, or dyslipidemia.
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for weight management and metabolic control. GLP-1 is a physiological hormone that helps regulate blood glucose levels by stimulating insulin secretion, reducing glucagon release, and slowing gastric emptying. Semaglutide, which is structurally similar to human GLP-1, binds selectively to GLP-1 receptors and exerts glucose-dependent effects that support weight reduction and metabolic balance.
At the recent SEC meeting, Alkem Laboratories Limited presented the Phase III CT report for Semaglutide Injection for chronic weight management. After detailed deliberation, the committee accepted the Phase III CT report and recommended the grant of permission for manufacture and marketing of Semaglutide Injection across the approved strengths.
However, the recommendation has been made subject to the condition that the firm must conduct a Post-Marketing Surveillance (PMS) study.
Indication
It is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of
• 30 kg/m2 or greater (obesity) or
• 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Accordingly, the expert panel directed that Alkem Laboratories Limited should submit the PMS study protocol to CDSCO within three months from the date of approval of the drug product for review by the committee.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.